Verily designed the lab to Freenome’s specifications to foster collaboration after quietly participating in its $65 million financing round in March.

Takeda and BioSurfaces are teaming up to create devices for the treatment of gastrointestinal disease based on the latter's nanofiber technology.

Sebacia raised $36 million to complete the U.S. pivotal trial of its gold-and-silica microparticle acne treatment.

Personal genomics player Helix has launched an online marketplace for “DNA-powered products,” including Sema4's saliva-based carrier test from Sema4.

The latest deal sees Alere agree to sell its Epocal point-of-care blood diagnostic unit to Siemens for an undisclosed sum.

Aspect Imaging has earned an FDA nod for its neonatal MRI device, designed for head and brain imaging in neonatal ICUs.

IBM and the University of Alberta developed algorithms that predict schizophrenia, which could lead to objective measures to diagnose the disorder.

The series B round equips Amphora to take its minimally invasive, cystoscopic device into the last step of clinical development next year.

Mayo Clinic and AliveCor are developing a low-cost, portable screening tool for long QT, which can cause sudden cardiac death.